A key therapeutic goal in CML is achieving sustained deep molecular response (DMR, BCR::ABL1 ≤ 0.01%), which may allow for treatment discontinuation aimed at treatment-free remission (TFR). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.